-

ENSG Investor Alert: Levi & Korsinsky Investigates The Ensign Group (ENSG) for Potential Securities Fraud

The Ensign Group lost significant market value after a short-seller report alleged systemic quality-measure gaming and improper billing practices at the skilled nursing facility operator.

NEW YORK--(BUSINESS WIRE)--Shares of The Ensign Group (NASDAQ: ENSG) dropped sharply on June 8, 2026, after Hunterbrook Media published a short-seller report alleging systemic neglect, quality-measure gaming, and improper related-party billing across the company's skilled nursing facilities. Shareholders who lost money on ENSG are encouraged to submit their information here. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

The sell-off came after the Hunterbrook report directly challenged claims made by CEO Barry Port on the Q1 2026 earnings call on May 1, 2026. On that call, Port stated that "85% of all of our operations are at 4- or 5-star quality measures" and that same-store occupancy had reached "new record highs during the quarter of 84.3% and 85.1%, respectively." The short-seller report alleged those quality ratings were gamed and that staffing levels were mischaracterized.

The market reaction was immediate. ENSG shares fell on heavy volume following the report's publication, erasing weeks of post-earnings gains in a single session. Prior to the report, ENSG had traded near its highs on the strength of the Q1 2026 results and raised guidance.

If you purchased The Ensign Group shares and suffered a loss, click here to get more information about the investigation. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500.

ABOUT THE FIRM -- For over two decades, Levi & Korsinsky has represented shareholders in securities investigations and actions. Ranked in ISS Top 50 for seven consecutive years.

Frequently Asked Questions About the ENSG Investigation

Q: Who is eligible to participate in the ENSG investigation? A: Investors who purchased ENSG stock and suffered financial losses may be eligible. Eligibility is based on purchase date and documented losses -- not on whether you still hold the shares.

Q: Which statements are being investigated as potentially misleading? A: The investigation concerns whether The Ensign Group made materially false or misleading statements regarding the quality of its skilled nursing operations, occupancy metrics, and staffing stability. When the Hunterbrook short-seller report challenged those claims, the stock price declined sharply.

Q: What do ENSG investors need to do right now? A: Gather brokerage records including purchase dates, share quantities, and prices paid. Contact Levi & Korsinsky for a free, no-obligation evaluation at jlevi@levikorsinsky.com or (212) 363-7500. No immediate action is required to remain eligible to participate in the investigation.

Q: What happens after I contact Levi & Korsinsky? A: An attorney will review your trading history at no cost and provide an initial assessment of your potential recovery.

Q: What if I already sold my ENSG shares -- can I still recover losses? A: Yes. Eligibility is based on when you purchased, not whether you still hold the shares. Investors who bought ENSG and sold at a loss may still participate in the investigation.

Q: What does it cost me to participate? A: Nothing. Securities investigations are handled on a pure contingency basis. No upfront fees, no retainer, no out-of-pocket costs.

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

Levi & Korsinsky, LLP

NASDAQ:ENSG

Release Versions

Contacts

Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 27th Floor
New York, NY 10004
jlevi@levikorsinsky.com
Tel: (212) 363-7500
Fax: (212) 363-7171

More News From Levi & Korsinsky, LLP

EYPT Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into EyePoint Pharmaceuticals (EYPT)

NEW YORK--(BUSINESS WIRE)--Roughly seven out of every ten dollars invested in EyePoint Pharmaceuticals (NASDAQ: EYPT) common stock was wiped out when shares fell nearly 67% following the Company's disclosure that DURAVYU missed the prespecified primary endpoint in the Phase 3 LUGANO wet AMD trial. If you held EYPT shares through that decline, you are encouraged to have your EYPT losses reviewed now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at...

GLOB Investor Alert: Levi & Korsinsky Notifies Investors of Investigation Into Globant (GLOB)

NEW YORK--(BUSINESS WIRE)--Shareholders of Globant (NYSE: GLOB) absorbed a sharp decline in the shares after the Company's Q2 2026 earnings release, which reported revenue of approximately $614.4 million and a reduced full-year 2026 revenue forecast. Investors who lost money on GLOB are encouraged to request a review of your GLOB losses now. You may also contact Joseph E. Levi, Esq. via email at jlevi@levikorsinsky.com or by telephone at (212) 363-7500. The reported quarter came in below street...

PRIM Deadline Alert: Levi & Korsinsky Reminds Primoris Services Corporation (PRIM) Investors of Securities Class Action Deadline on September 21, 2026

NEW YORK--(BUSINESS WIRE)--Levi & Korsinsky, LLP notifies investors in Primoris Services Corporation (NYSE: PRIM) that a class action has been filed on behalf of shareholders who purchased securities between August 5, 2025 and June 22, 2026. See if you could be eligible to recover or call (212) 363-7500.PRIM fell $23.39 per share, or 21.6%, from $108.34 to $84.95 on June 23, 2026. The lead plaintiff deadline is September 21, 2026.Primoris Timeline Disclosure Events Alleged in the ComplaintTh...
Back to Newsroom